ResultsIQ

ResultsIQ › Latest results › Epigral Limited

Epigral Limited Q4 FY25 earnings call summary

NSE: EPIGRAL · BSE: 543332

Earnings call of 5 May 2025, summarised by AI from the filing.

Derivatives & Specialty business contributed 54% of FY25 revenue vs 45%, driving growth.

Key takeaways

  1. Driver Derivatives & Specialty business contributed 54% of FY25 revenue vs 45%, driving growth.
  2. Risk Chemical industry growth is slower and product/region specific; hydrogen peroxide realizations dropped.

Original filing on BSE

Epigral Limited Q1 FY27 results

As filed: Revenue ₹705 cr (+16% year on year), EBITDA ₹179 cr (+9% year on year), PAT ₹99.7 cr (−38% year on year), EBITDA margin 25.4% (−161 bps).

The Q1 FY27 score, against the company's own trend, is for premium members.

Earlier results and the share price after them

  • Q4 FY26: Revenue ₹736 cr (+17% year on year), EBITDA ₹169 cr (−3% year on year), PAT ₹81.0 cr (−7% year on year), EBITDA margin 22.9% (−481 bps). Score 55 of 100, In line with trend. Revenue and EBITDA growth were in line with the company's own trend; profit growth was below it. EBITDA margin fell 481 bps year on year. Revenue grew on the previous quarter, against its usual seasonal pattern. Share price after the results: −4.8% in 30 days (Nifty 500: −1.1%).
  • Q3 FY26: Revenue ₹597 cr (−7% year on year), EBITDA ₹103 cr (−44% year on year), PAT ₹39.1 cr (−62% year on year), EBITDA margin 17.2% (−1,000 bps). Score 18 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 1000 bps year on year. Profit fell 23% from last quarter. Share price after the results: −6.3% in 28 days (Nifty 500: +0.1%).
  • Q2 FY26: Revenue ₹587 cr (−6% year on year), EBITDA ₹132 cr (−25% year on year), PAT ₹51.0 cr (−37% year on year), EBITDA margin 22.5% (−579 bps). Score 14 of 100, Below trend. Revenue, EBITDA and profit growth were well below the company's own trend. EBITDA margin fell 579 bps year on year. Revenue fell 3% from last quarter. Share price after the results: −13.2% in 30 days (Nifty 500: −0.5%).
  • Q1 FY26: Revenue ₹607 cr (−7% year on year), EBITDA ₹164 cr (−7% year on year), PAT ₹161 cr (+87% year on year), EBITDA margin 27.0% (−2 bps). Score 41 of 100, In line with trend. EBITDA margin was flat year on year. Tax rate -50%. Not enough history for a trend yet: scored on growth alone. Revenue fell 3% from last quarter. Share price after the results: −7.6% in 30 days (Nifty 500: +0.2%).
  • Q4 FY25: Revenue ₹628 cr (+20% year on year), EBITDA ₹174 cr (+12% year on year), PAT ₹87.0 cr (+13% year on year), EBITDA margin 27.7% (−182 bps). Score 53 of 100, In line with trend. EBITDA margin fell 182 bps year on year. Not enough history for a trend yet: scored on growth alone. Profit fell 16% from last quarter. Share price after the results: +0.7% in 30 days (Nifty 500: +3.6%).
  • Q3 FY25: Revenue ₹645 cr (+37% year on year), EBITDA ₹183 cr (+49% year on year), PAT ₹104 cr (+112% year on year), EBITDA margin 28.4% (+231 bps). Score 92 of 100, Above trend. EBITDA margin rose 231 bps year on year. Not enough history for a trend yet: scored on growth alone.
  • Q2 FY25: Revenue ₹626 cr (+31% year on year), EBITDA ₹177 cr (+64% year on year), PAT ₹81.0 cr (+113% year on year), EBITDA margin 28.3% (+568 bps). Score 85 of 100, Above trend. EBITDA margin rose 568 bps year on year. Tax rate 35%. Not enough history for a trend yet: scored on growth alone. Revenue fell 4% from last quarter.

Past price moves after results do not indicate future moves. Not a recommendation.

Epigral Limited earnings call, investor presentation and press release summaries

Figures from the company's filings with NSE and BSE. Not investment advice.